New cell implant aims to curb severe low blood sugar in type 1 diabetes
NCT ID NCT06651515
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment called SR-02, which involves implanting insulin-producing cells into the abdomen of adults with type 1 diabetes who experience dangerously low blood sugar. Participants would need to take lifelong anti-rejection drugs to prevent the body from attacking the implanted cells. The study was withdrawn before enrolling anyone, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Presbyterian Shadyside
Pittsburgh, Pennsylvania, 15213, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a stress hormone be behind the hidden danger of low blood sugar?
- Can a peptide tame type 1 diabetes?
- Can a tiny implant track glucose, ketones, and lactate in diabetes?
- Wearable sensor could unmask hidden blood sugar chaos in stomach paralysis
- A smarter insulin that aims for the liver could curb dangerous nighttime dips
- Smart insulin pump may boost brain and body health in older adults with diabetes